Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MiRacle Consortium Receives a € 1.2 Million FP7 Grant from the European Union

Published: Monday, November 04, 2013
Last Updated: Monday, November 04, 2013
Bookmark and Share
Therapeutic development of cancer cell-specific targeting of novel tumor-selective lethal miRNAs for the treatment of head and neck cancer – acronym: MiRacle.

InteRNA Technologies B.V. and VU University Medical Center (VUmc) announce today they have been granted funding from the European Union’s FP7program “Research for the benefit of SMEs”. InteRNA and VUmc, who are leading this consortium, together with Quiet Therapeutics Ltd (Israel), a biopharma SME engaged in the development of a new class of highly selective targeted therapeutics for oncology and inflammation, have been granted around € 1.2 million, to develop the targeted delivery of novel tumor-selective lethal miRNAs for the treatment of head and neck cancer. The consortium further includes BioSpring (Germany), OctoPlus (the Netherlands) and the Laboratory of Pharmacology and Toxicology LPT (Germany).

MiRacle focuses on the development of a targeted therapeutic formulation for the treatment of head and neck cancer. Head and neck (H&N) cancer is the sixth most common cancer worldwide and the incidence increases. Unfortunately the majority of H&N cancer patients present with advanced stages of disease. These patients frequently develop locoregional recurrences, distant metastasis and/or second primary tumors resulting in 5-years survival rates of less than 60% The development of novel anti-cancer agents to improve outcome is therefore urgently awaited.

The goal of MiRacle is the advancement of the safe, targeted delivery of therapeutic tumor-selective lethal miRNA formulation towards the clinic by combining two innovative technologies, i.e. application of therapeutic miRNAs using cancer cell-specific targeted drug delivery.

Besides the expertise on the therapeutic application of miRNA and the in depth knowledge of the therapeutic indication, e.g. H&N cancer, the MiRacle consortium brings together the knowledge on the synthesis of biochemical active miRNAs, the expertise in drug formulation to specifically deliver therapeutic miRNA into humans, the understanding for synthesis of complex drug formulations, the preclinical testing, and the skillfulness in toxicity tests that are required for RNA based drug registration.

 “The unique tumor-selective lethal miRNAs identified display a very interesting biology and potential therapeutic effect that warrants further development towards the clinic. This FP7 grant exemplifies that with this consortium we have all the expertise in place to bring a tumor killing miRNA in a targeted and safe manner towards registration for first in human testing”, said Roel Schaapveld, Chief Executive Officer of InteRNA Technologies.

“This FP7 grant enables the next step in the translation of the tumor-selective lethal microRNAs that we discovered” said Ruud Brakenhof, Professor of Cancer Genetics, Tumor Biology Section at the Department of Otolaryngology/Head-Neck Surgery of VUmc.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Genetic Impact of Endurance Training
Research has found that endurance training changes genetic activity in thousands of genes, giving rise to large number of altered RNA variants.
Wearable Microscope Can Measure Fluorescent Dyes Through Skin
UCLA research could make monitoring disease biomarkers easier and more cost-effective.
“Sixth Sense” More Than a Feeling
NIH study of rare genetic disorder reveals importance of touch and body awareness.
A Diversity of Genomes
New DNA from understudied groups reveals modern genetic variation, ancient population shifts.
Gene Could Reduce Female Mosquitoes
Virginia Tech researchers have found a gene that can reduce female mosquitoes over many generations.
Improving Crop Efficiency with CRISPR
New study of CRISPR-Cas9 technology from Virginia Tech shows potential to improve crop efficiency.
Examining mtDNA May Help Identify Unknown Ancestry That Influences Breast Cancer Risk
Researchers studying mtDNA in a group of triple negative breast cancer patients found that 13 percent of participants were unaware of ancestry that could influence their risk of cancer.
Bacteria Use Ranking Strategy to Fight Off Viruses
Researchers have explained why microbes store virus confrontation information sequentially, with most recent attacks first.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!